saving the inoperable and untreatable patinets with nano/micro particle as a medical device

We are a startup to develop a novel tiny particle for unmet medical needs such as cancer and chronic pain, which particle is self-targeting to the tumor vessel, repeatable and degradable as a platform technology for further applications. Our unique particle is patent granted in Japan, now under transferring to the US, EU and China now. The first indication for human clinical trial will be HCC (hepato-cellular carcinoma) to replace TACE (trans-catheter chemoembolization) treatment which is the current primary option for the intermediate stage of HCC and to be a primary option other than shifting to chemotherapy. The other advantages are universal to every solid tumor, locoregional work at tumor tissue only, combinatory because of drug free and gentle for the weaken patient without additional physical burden. We can expect the extension of PFS (progression free survival) and OS (overall survival) rather than the high response of the advanced chemotherapy such as molecular target medicine and immunotherapy with severe side effects and drug escalations. The potential market for liver cancer only will be near 1 billion dollars per year. So, after the extension to the other solid tumors, it will be easily over several billions. The current definition of our particle is a medical device (category III by FDA), but it can become a functional matter after labeling other functions as a medicine. We are looking for the investors, collaboration partners and medical institutions for the global clinical trials.

OUR PRODUCT
http://www.medigear.co.jp/en

We are a startup to develop a novel tiny particle for unmet medical needs such as cancer and chronic pain, which particle is self-targeting to the tumor vessel, repeatable and degradable as a platform technology for further applications. Our unique particle is patent granted in Japan, now under transferring to the US, EU and China now. The first indication for human clinical trial will be HCC (hepato-cellular carcinoma) to replace TACE (trans-catheter chemoembolization) treatment which is the current primary option for the intermediate stage of HCC and to be a primary option other than shifting to chemotherapy. The other advantages are universal to every solid tumor, locoregional work at tumor tissue only, combinatory because of drug free and gentle for the weaken patient without additional physical burden. We can expect the extension of PFS (progression free survival) and OS (overall survival) rather than the high response of the advanced chemotherapy such as molecular target medicine and immunotherapy with severe side effects and drug escalations. The potential market for liver cancer only will be near 1 billion dollars per year. So, after the extension to the other solid tumors, it will be easily over several billions. The current definition of our particle is a medical device (category III by FDA), but it can become a functional matter after labeling other functions as a medicine. We are looking for the investors, collaboration partners and medical institutions for the global clinical trials.

Contact
takeot17@medigear.co.jp
CEO
Takeo Tanaka
founder and CEO
www.linkedin.com/in/takeo-tanaka-43a40447
FOUNDER
Takeo Tanaka
CEO
www.linkedin.com/in/takeo-tanaka-43a40447
Voice from Acceralator
Berkeley SkyDeck

MediGear is developing a nano device for inoperable cancer patients as a starvation treatment. MediGear is still finalizing their business model, and realized it is critical to make their solution a platform technology after talking with SkyDeck advisors and investors. That’s also key to attracting investors outside of Japan. The CEO and CTO are a great team together.